Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.nrleng.2025.09.004 http://scihub22266oqcxt.onion/10.1016/j.nrleng.2025.09.004 40914455!ä!40914455 Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=40914455&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\40914455.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Neurologia+(Engl+Ed) 2025 ; ä (ä): ä Nephropedia Template TP {{tp|p=40914455|t=2025. Immune-mediated necrotizing myopathy: an emerging disorder |pdf=|usr=}}{{40914455}} gab.com Text Immune-mediated necrotizing myopathy: an emerging disorder JO: Neurologia (Engl Ed) http://www.kidney.de/pget.php?&tw=1&pmid=40914455 #FOAvip OBJECTIVES: To describe the main features and the clinical management of a cohort of patients with immune-mediated necrotizing myopathy (IMNM). METHODS: We conducted an observational, monocentric, retrospective study of IMNM patients diagnosed in the Neuromuscular Unit of a tertiary hospital in Madrid (Spain) between 2013 and 2021. RESULTS: Sixteen IMNM cases were diagnosed, with a median age of 71.5 years (range 36-80), nine of whom (56.3%) were female. Thirteen (81.3%) patients had previously been treated with statins. The time from symptoms onset to diagnosis was less than six months in eleven (68.8%) patients and the most common clinical symptoms were proximal weakness and myalgia. The only myositis specific autoantibodies detected were anti-3-hydroxy-3-methyl-coenzyme A reductase in thirteen patients. The treatment strategy was based on prednisone, although a combination with other immunosuppressive drugs was required in eight (50%) patients. CONCLUSIONS: There has been an increase in the diagnosis of immune-mediated necrotizing myopathies in the last few years. The anti-HMGCR antibodies were the only detected in this sample showing their key role in the diagnosis. Early recognition of the disease facilitate to start treatment as soon as possible, which should be based on the initial response to corticosteroids and usually requires a combination of several drugs. Twit Text FOAVip Immune-mediated necrotizing myopathy: an emerging disorder ????Neurologia (Engl Ed) http://www.kidney.de/pget.php?&tw=1&pmid=40914455 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=40914455 #FOAvip English Wikipedia <ref>{{Cite pmid|40914455}}</ref> Immune-mediated necrotizing myopathy: an emerging disorder #MMPMID40914455 Portela-Sanchez S; Catalina I; Lopez Munoz S; Lozano Ros A; Sanchez-Soblechero A; Sola Vendrel E; Sanchez-Mateos P; Munoz-Blanco JL Neurologia (Engl Ed) 2025[Sep]; ä (ä): ä PMID40914455show ga OBJECTIVES: To describe the main features and the clinical management of a cohort of patients with immune-mediated necrotizing myopathy (IMNM). METHODS: We conducted an observational, monocentric, retrospective study of IMNM patients diagnosed in the Neuromuscular Unit of a tertiary hospital in Madrid (Spain) between 2013 and 2021. RESULTS: Sixteen IMNM cases were diagnosed, with a median age of 71.5 years (range 36-80), nine of whom (56.3%) were female. Thirteen (81.3%) patients had previously been treated with statins. The time from symptoms onset to diagnosis was less than six months in eleven (68.8%) patients and the most common clinical symptoms were proximal weakness and myalgia. The only myositis specific autoantibodies detected were anti-3-hydroxy-3-methyl-coenzyme A reductase in thirteen patients. The treatment strategy was based on prednisone, although a combination with other immunosuppressive drugs was required in eight (50%) patients. CONCLUSIONS: There has been an increase in the diagnosis of immune-mediated necrotizing myopathies in the last few years. The anti-HMGCR antibodies were the only detected in this sample showing their key role in the diagnosis. Early recognition of the disease facilitate to start treatment as soon as possible, which should be based on the initial response to corticosteroids and usually requires a combination of several drugs. äImmune-mediated necrotizing myopathy: an emerging disorder (epmc).pdf DeepDyve Pubget Overpricing